Accelrys stays on growth track in Q4

Accelrys ($ACCL) has bested analysts' estimates on the San Diego company's revenue for the fourth quarter. The provider of lab software for biopharma groups recorded $39.8 million in quarterly revenue--better than the $38.7 million analysts had predicted, Daily Finance reports. Accelrys has seen its overall growth accelerate in recent years through a series of buyouts of companies such as Symyx, Contur and VelQuest. Report